FDA Accepts To Review Verona Pharma's New Drug Application For Ensifentrine For Maintenance Treatment Of Chronic Obstructive Pulmonary Disease, With PDUFA Target Action Date Of June 26, 2024
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved a New Drug Application for Verona Pharma's Ensifentrine, a maintenance treatment for Chronic Obstructive Pulmonary Disease.
September 11, 2023 | 6:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verona Pharma's stock may see a positive impact due to the FDA approval of its new drug, Ensifentrine.
FDA approval of a new drug is a significant milestone for pharmaceutical companies. This approval can lead to increased revenues from the sales of the drug, which can positively impact the company's stock price. Therefore, Verona Pharma's stock (VRNA) is likely to see a positive impact in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100